Clario, a healthcare research technology company specializing in clinical trial solutions, has announced a collaborative effort with the University of Oxford, aimed at advancing the understanding of motor symptom progression in Parkinson's Disease. This collaboration holds promise for enhancing future neuroscience clinical trials and treatments.

Through a comprehensive study utilizing Clario's wearable sensor technology and machine learning, researchers have succeeded in providing more accurate tracking of motor symptom progression in Parkinson's Disease compared to traditional clinical rating scales. Notably, the wearable technology detected disease progression in a significantly shorter time frame.

Clario's extensive expertise in both scientific and technical domains facilitated the precise collection of digital movement data, enabling early detection of disease progression. This breakthrough has the potential to expedite the development of new medications for Parkinson's Disease and offer earlier intervention options for patients grappling with this challenging condition. It underscores the significance of employing wearable technology and machine learning algorithms for more precise tracking of Parkinson's Disease progression and assessing the effectiveness of early therapeutic measures, holding great promise for neuroscience clinical trials.

Source: prnewswire.com